Payment overview · 2025
General Payments
$361.26
16 reported records · 6 companies
Healthcare provider profile · identity verified
Ankhnu Uaskhem, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BROOKLYN, NY · NPI 1982797197
Verified facts
What the public records show
CMS Open Payments records show Ankhnu Uaskhem, M.D. received $361.26 in general payments during 2025 across 16 reported records.
Novartis Pharmaceuticals Corporation accounted for 38.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga, Mounjaro, Otezla, Ozempic, Rybelsus.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 311 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 301 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 542 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $138.89 | 38.5% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $74.82 | 20.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $69.79 | 19.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.23 | 10.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.14 | 6.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.39 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $361.26 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $110.53 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $69.79 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $56.36 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.22 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $28.36 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 193 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 106 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 311 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 73 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 542 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
311 | 44 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
301 | 56 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
73 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
171 | 24 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
106 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
542 | 79 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
193 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1353 | 269 |
| Amlodipine Besylate | Amlodipine Besylate | 949 | 178 |
| Losartan Potassium | Losartan Potassium | 794 | 148 |
| Metoprolol Succinate | Metoprolol Succinate | 663 | 123 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 641 | 96 |
| Ozempic | Semaglutide | 542 | 79 |
| Warfarin Sodium | Warfarin Sodium | 515 | 22 |
| Nifedipine Er | Nifedipine | 466 | 79 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 436 | 80 |
| Valsartan | Valsartan | 393 | 75 |
| Metformin Hcl | Metformin Hcl | 390 | 70 |
| Gabapentin | Gabapentin | 340 | 68 |
| Metformin Hcl Er | Metformin Hcl | 313 | 67 |
| Farxiga | Dapagliflozin Propanediol | 311 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 304 | 39 |
| Jardiance | Empagliflozin | 301 | 56 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 293 | 92 |
| Enalapril Maleate | Enalapril Maleate | 263 | 51 |
| Chlorthalidone | Chlorthalidone | 242 | 45 |
| Omeprazole | Omeprazole | 240 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 214 | 46 |
| Furosemide | Furosemide | 209 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 199 | 36 |
| Famotidine | Famotidine | 195 | 41 |
| Eliquis | Apixaban | 193 | 33 |
| Carvedilol | Carvedilol | 190 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 177 | 28 |
| Montelukast Sodium | Montelukast Sodium | 176 | 31 |
| Trulicity | Dulaglutide | 171 | 24 |
| Xarelto | Rivaroxaban | 169 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 153 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 37 |
| Tradjenta | Linagliptin | 145 | 19 |
| Lidocaine | Lidocaine | 144 | 23 |
| Alendronate Sodium | Alendronate Sodium | 140 | 20 |
| Ezetimibe | Ezetimibe | 140 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 131 | 24 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 123 | 20 |
| Entresto | Sacubitril/Valsartan | 106 | 18 |
| Lisinopril | Lisinopril | 106 | 19 |
| Januvia | Sitagliptin Phosphate | 100 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 21 |
| Azelastine Hcl | Azelastine Hcl | 92 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 92 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 18 |
| Atenolol | Atenolol | 89 | 12 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 89 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 85 | 17 |
| Ibandronate Sodium | Ibandronate Sodium | 80 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 79 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 76 | 27 |
| Memantine Hcl | Memantine Hcl | 76 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 74 | 28 |
| Allopurinol | Allopurinol | 73 | 15 |
| Mounjaro | Tirzepatide | 73 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 14 |
| Spironolactone | Spironolactone | 68 | 14 |
| Levetiracetam | Levetiracetam | 63 | 13 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 61 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 59 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 56 | 11 |
| Simvastatin | Simvastatin | 55 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 12 |
| Donepezil Hcl | Donepezil Hcl | 53 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 53 | suppressed |
| Topiramate | Topiramate | 53 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 52 | 17 |
| Prednisone | Prednisone | 50 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | suppressed |
| Finasteride | Finasteride | 45 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 45 | 18 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 44 | suppressed |
| Glipizide | Glipizide | 44 | suppressed |
| Ketoconazole | Ketoconazole | 44 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 43 | 12 |
| Meloxicam | Meloxicam | 43 | suppressed |
| Rybelsus | Semaglutide | 43 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 40 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 18 |
| True Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 39 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 38 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 38 | 13 |
| Azithromycin | Azithromycin | 37 | 28 |
| Folic Acid | Folic Acid | 37 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 37 | suppressed |
| Glipizide Er | Glipizide | 36 | suppressed |
| Hydrocortisone | Hydrocortisone | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 34 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 33 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 11 |
| Naproxen | Naproxen | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 30 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 17 |
| Methimazole | Methimazole | 29 | suppressed |
| Nystatin | Nystatin | 29 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 27 | suppressed |
| Calcitriol | Calcitriol | 26 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 26 | suppressed |
| Kerendia | Finerenone | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Clotrimazole | Clotrimazole | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 16 |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 21 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 20 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Terconazole | Terconazole | 18 | 11 |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Procto-Med Hc | Hydrocortisone | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Corlanor | Ivabradine Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Repatha Syringe | Evolocumab | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Otezla | Apremilast | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Desonide | Desonide | 12 | suppressed |
| Desoximetasone | Desoximetasone | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $361.26 · 16 records | Novartis Pharmaceuticals Corporation | AIRSUPRA, ELIQUIS, ENTRESTO, FARXIGA, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error